FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates
In this article:
The Food and Drug Administration rejected Lykos’ application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.